NCT02899091

Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease

A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: CHABiotech CO., Ltd · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate safety and potential therapeutic effect of intraveneously administered CB-AC-02 in patients with Alzheimer's Disease.

Detailed description

Subjects will receive either the single or multiple doses of CB-AC-02 to be followed up and evaluated for safety and potential therapeutic effect

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
BIOLOGICAL	CB-AC-02	Stage1: ① Group1: CB-AC-02 administration on day 0 ② Group2: CB-AC-02 administration on day 0 and on week 4 (repeated injection) Stage2 ① Arm1: K-MMSE 20\~26 CB-AC-02 administration on day 0 and on week 4 (repeated injection) ② Arm2: K-MMSE 10\~19 CB-AC-02 administration on day 0 and on week 4 (repeated injection)
BIOLOGICAL	Placebo	Stage2: Placebo administration on day 0 and on week 4 (repeated injection)

Timeline

• Start date: 2016-09-01
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2016-09-14
• Last updated: 2024-04-09

Locations

1 site across 1 country: South Korea